Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2020

Research By Markets adds Market Research Report - Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2020

For detailed information: https://www.researchbymarkets.com/report/chronic-obstructive-pulmonary-disease-copd-pipeline-review-h2-2020-665863.html

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2020

Summary

Chronic Obstructive Pulmonary Disease – Pipeline Review, H2 2020, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

Chronic Obstructive Pulmonary Disease – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 8, 34, 13, 3, 82, 22 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
– The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
3SBio Inc
AB Science SA
AB2 Bio Ltd
Adamis Pharmaceuticals Corp
Afimmune Biopharma Ltd
Aibios Co Ltd
AlgiPharma AS
Allinaire Therapeutics LLC
Amgen Inc
Angiocrine Bioscience Inc
Apollo Therapeutics LLC
Aquilon Pharmaceuticals SA
Aridis Pharmaceuticals Inc
Ark Biosciences Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Atriva Therapeutics GmbH
AusBio Ltd
Avidin Biotechnology Ltd
Axolo Pharma Inc
Bai Shuo Beijing Pharmaceutical Technology Co Ltd
Bayer AG
BioMarck Pharmaceuticals Ltd
Boehringer Ingelheim International GmbH
Brickell Biotech Inc
C4X Discovery Holdings Plc
Cambryn Biologics LLC
Celon Pharma SA
Chiesi Farmaceutici SpA
Cipla Ltd
Circassia Group Plc
Covenant Therapeutics LLC
CSL Ltd
Cureveda LLC
Cytokinetics Inc
Denovo Biopharma LLC
Diadem Biotherapeutics Inc
Diffusion Pharmaceuticals Inc
Dimerix Ltd
Domainex Ltd
EmeraMed Ltd
EmphyCorp Inc
Emphymab Biotech LLC
Enzychem Lifesciences Corp
EpiEndo Pharmaceuticals Ehf
Epitracker Inc
Errant Gene Therapeutics LLC
ethris GmbH
Evaxion Biotech ApS
Exotect LLC
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Future Medicine Co Ltd
Galapagos NV


For queries regarding this report: https://www.researchbymarkets.com/sample-request/665863

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.